PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29715111
OWN - NLM
STAT- MEDLINE
DCOM- 20180515
LR  - 20180515
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 5
DP  - 2018 May
TI  - Chemotherapy or Combined Modality Therapy for Early-stage Hodgkin Lymphoma.
PG  - 2875-2881
AB  - BACKGROUND/AIM: Optimizing treatment of early-stage Hodgkin lymphoma (HL)
      requires balancing cure with potential acute and late toxicities from treatment. 
      We reviewed our institutional experience with chemotherapy alone (ChT) versus
      combined modality therapy (CMT). MATERIALS AND METHODS: Patients with stage I-II 
      classical HL in a complete response (CR) by functional imaging after chemotherapy
      were included. Progression-free survival (PFS) and overall survival (OS) were
      calculated and a multivariate analysis (MVA) was performed. RESULTS: A total of
      136 patients with a CR to chemotherapy were identified. Consolidation radiation
      therapy (RT) was administered to 117 while 19 received no further therapy. PFS (5
      years) was 97% with CMT and 84% with chemotherapy alone (p=0.02). Long-term (10
      year) survival was no different (96 vs. 94%, p=0.8). On MVA, CMT improved PFS.
      Secondary malignancies were rare and no cardiac events were observed. CONCLUSION:
      Consolidation RT results in superior PFS in early-stage Hodgkin lymphoma with
      minimal added toxicity.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Torok, Jordan A
AU  - Torok JA
AD  - Department of Radiation Oncology, Duke University, Durham, NC, U.S.A.
FAU - Wu, Yuan
AU  - Wu Y
AD  - Department of Biostatistics and Bioinformatics, Duke University, Durham, NC,
      U.S.A.
FAU - Chino, Junzo
AU  - Chino J
AD  - Department of Radiation Oncology, Duke University, Durham, NC, U.S.A.
FAU - Prosnitz, Leonard R
AU  - Prosnitz LR
AD  - Department of Radiation Oncology, Duke University, Durham, NC, U.S.A.
FAU - Beaven, Anne W
AU  - Beaven AW
AD  - Department of Medicine, Division of Medical Oncology, University of North
      Carolina, Chapel Hill, NC, U.S.A.
FAU - Kim, Grace J
AU  - Kim GJ
AD  - Department of Radiation Oncology, Duke University, Durham, NC, U.S.A.
FAU - Kelsey, Chris R
AU  - Kelsey CR
AD  - Department of Radiation Oncology, Duke University, Durham, NC, U.S.A.
      [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Chemoradiotherapy/*methods
MH  - Disease-Free Survival
MH  - Female
MH  - Hodgkin Disease/*drug therapy/mortality/*radiotherapy
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Proportional Hazards Models
MH  - Radiotherapy, Adjuvant/methods
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - *Radiation therapy
OT  - *complete response
OT  - *consolidation
OT  - *metabolic imaging
OT  - *positron emission tomography
EDAT- 2018/05/02 06:00
MHDA- 2018/05/16 06:00
CRDT- 2018/05/02 06:00
PHST- 2018/03/01 00:00 [received]
PHST- 2018/03/16 00:00 [revised]
PHST- 2018/03/19 00:00 [accepted]
PHST- 2018/05/02 06:00 [entrez]
PHST- 2018/05/02 06:00 [pubmed]
PHST- 2018/05/16 06:00 [medline]
AID - 38/5/2875 [pii]
AID - 10.21873/anticanres.12533 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 May;38(5):2875-2881. doi: 10.21873/anticanres.12533.